Xerostomia Management for Pediatric Oncology Patients with Lactoperoxidase Included Oral Health Care Products
- *Corresponding Author:
- Ilknur Tanboga
Department of Paediatric Dentistry
Dental School, Marmara University
Buyukciftlik Sok No: 6, Kat: 4
34365, Istanbul, Turkey
E-mail: [email protected]
Received date: November 28, 2011; Accepted date: December 25, 2011; Published date: January 03, 2012
Citation: Tanboga I, Durmus B, Karakas Z, Saribeyoglu E, Yalcinkaya D, et al. (2012) Xerostomia Management for Pediatric Oncology Patients with Lactoperoxidase Included Oral Health Care Products. Dentistry 3:158. doi: 10.4172/2161-1122.1000158
Copyright: © 2012 Tanboga I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: Evaluating the efficacy of lactoperoxidase included oral care products for xerostomia in children with cancer undergoing chemotherapy and / or radiotherapy and to present an easy to follow oral care protocol.
Design: The study subjects consisted of twenty one pediatric cancer patients (mean age of 11,3±) with either leukemia or lymphoma used lactoperoxidase-system-containing mouth rinse (Biotene®) combined with (Biotene®) gel or (Biotene®) chewing gum for 3 weeks. Unstimulated saliva samples were collected at the base line and 4 weeks after the usage of the products. They were analyzed for selected biochemical factors and subjective symptoms as intra-oral dryness (xerostomia), eating ability and oral discomfort were graded by visual analogue scale.
Results: No major changes occurred in the level of saliva Thiocyanite and Peroxidase activity, but there was a increase in salivary pH and also salivary flow rate was notably higher in groups using Lactoperoxidase products. Changes related to buffering capacity of saliva were also recorded. Conclusion: There is no clearly effective treatment for xerostomia but we have observed in our practice that the use of non-immunologic antimicrobial agents relieves subjective oral symptoms in most xerostomic pediatric patients.